journal article·2025-01Open access

Targeting tRNA‐Derived Non‐Coding RNA Alleviates Diabetes‐Induced Visual Impairment through Protecting Retinal Neurovascular Unit

Jin Yao, Wen Yao, Jun‐Ya Zhu, Yan Liu, Jin‐Hong Liu, Yu‐Ke Ji, Xi‐Shen Ni, Wan Mu, Biao Yan

Advanced Science· Volume 12· Issue 1

Abstract

Abstract Diabetes is a major risk factor for compromised visual health, leading to retinal vasculopathy and neuropathy, both of which are hallmarks of neurovascular unit dysfunction. Despite the critical impact of diabetic retinopathy, the precise mechanism underlying neurovascular coupling and effective strategies to suppress neurovascular dysfunction remain unclear. In this study, the up‐regulation of a tRNA‐derived stress‐induced RNA, 5′tiRNA‐His‐GTG, in response to diabetic stress is revealed. 5′tiRNA‐His‐GTG directly regulates Müller glia action and indirectly alters endothelial angiogenic effects and retinal ganglion cell (RGC) survival in vitro. Downregulation of 5′tiRNA‐His‐GTG alleviates diabetes‐induced retinal neurovascular dysfunction, characterized by reduced retinal vascular dysfunction, decreased retinal neurodegeneration, and improved visually‐guided behaviors in vivo. Mechanistically, 5′tiRNA‐His‐GTG acts as a key regulator of retinal neurovascular dysfunction, primarily by modulating arachidonic acid (AA) metabolism via the CYPs pathway. The 5′tiRNA‐His‐GTG‐CYP2E1‐19(S)‐HETE signaling axis is identified as a key driver of retinal neurovascular dysfunction. Thus, targeting 5′tiRNA‐His‐GTG presents a promising therapeutic strategy for treating vasculopathy and neuropathy associated with diabetes mellitus. Modulating this novel signaling pathway can open up new avenues for intervention in diabetic retinopathy and its related complications.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA modifications and cancer · Cancer-related molecular mechanisms research · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Affiliated Eye Hospital Nanjing Medical University Nanjing 210000 China

School of Medicine Southeast University Nanjing 210009 China

Department of Ophthalmology Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200080 China

Eye Institute and Department of Ophthalmology Eye and ENT Hospital Fudan University Shanghai 200031 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province

References (57)

Show source-provided references
1. 10.1161/ATVBAHA.117.31022110.1161/ATVBAHA.117.310221 ↗
2. 10.1016/j.ophtha.2021.04.02710.1016/j.ophtha.2021.04.027 ↗
3. A. Diabetes Care · 2011 · 34 · S6210.2337/dc11-S062 ↗
4. 10.1038/s41581-019-0234-410.1038/s41581-019-0234-4 ↗
5. 10.1038/s41581-020-0278-510.1038/s41581-020-0278-5 ↗
6. 10.1038/s41572-019-0092-110.1038/s41572-019-0092-1 ↗
7. 10.1016/j.preteyeres.2021.10103910.1016/j.preteyeres.2021.101039 ↗
8. 10.1016/S2213-8587(21)00113-310.1016/S2213-8587(21)00113-3 ↗
9. 10.1002/advs.20210246610.1002/advs.202102466 ↗
10. 10.1101/gad.178760910.1101/gad.1787609 ↗
11. 10.1016/j.cmet.2019.03.00910.1016/j.cmet.2019.03.009 ↗
12. 10.1093/nar/gkac02210.1093/nar/gkac022 ↗
13. 10.1007/s11427-020-1700-910.1007/s11427-020-1700-9 ↗
14. 10.1016/j.molcel.2011.06.02210.1016/j.molcel.2011.06.022 ↗
15. 10.1038/s41392-020-00217-410.1038/s41392-020-00217-4 ↗
16. 10.1016/j.stem.2021.08.01410.1016/j.stem.2021.08.014 ↗
17. 10.1111/jcmm.1751110.1111/jcmm.17511 ↗
18. 10.1080/15476286.2020.173269410.1080/15476286.2020.1732694 ↗
19. 10.1186/s13073-021-00833-x10.1186/s13073-021-00833-x ↗
20. 10.1016/j.neuroscience.2020.03.01810.1016/j.neuroscience.2020.03.018 ↗
21. 10.1038/s41574-020-00451-410.1038/s41574-020-00451-4 ↗
22. 10.3390/antiox910090510.3390/antiox9100905 ↗
23. 10.1186/s12974-015-0368-710.1186/s12974-015-0368-7 ↗
24. 10.3389/fcell.2021.75296210.3389/fcell.2021.752962 ↗
25. 10.1016/j.tem.2021.10.00810.1016/j.tem.2021.10.008 ↗
26. 10.1167/iovs.18-2529410.1167/iovs.18-25294 ↗
27. 10.3389/fimmu.2021.76309210.3389/fimmu.2021.763092 ↗
28. 10.3390/cancers1305108510.3390/cancers13051085 ↗
29. 10.1016/j.preteyeres.2015.06.00310.1016/j.preteyeres.2015.06.003 ↗
30. 10.2337/db11-031510.2337/db11-0315 ↗
31. 10.3390/nu1404079210.3390/nu14040792 ↗
32. 10.1016/j.tem.2013.09.00510.1016/j.tem.2013.09.005 ↗
33. 10.7150/ijbs.3524510.7150/ijbs.35245 ↗
34. 10.1124/dmd.123.00126710.1124/dmd.123.001267 ↗
35. 10.2337/db09-166810.2337/db09-1668 ↗
36. 10.3390/nu1409178410.3390/nu14091784 ↗
37. 10.2337/dc12-180510.2337/dc12-1805 ↗
38. 10.1186/s12943-023-01742-w10.1186/s12943-023-01742-w ↗
39. 10.1016/j.preteyeres.2011.02.00410.1016/j.preteyeres.2011.02.004 ↗
40. 10.1212/WNL.000000000020772710.1212/WNL.0000000000207727 ↗
41. 10.1001/jamaneurol.2018.156310.1001/jamaneurol.2018.1563 ↗
42. 10.3389/fnagi.2021.62833610.3389/fnagi.2021.628336 ↗
43. 10.1038/s41419-022-05387-310.1038/s41419-022-05387-3 ↗
44. 10.1016/j.neuron.2017.07.03010.1016/j.neuron.2017.07.030 ↗
45. 10.1007/s00125-018-4692-110.1007/s00125-018-4692-1 ↗
46. 10.1016/j.ophtha.2010.04.00110.1016/j.ophtha.2010.04.001 ↗
47. 10.1007/s11481-023-10073-y10.1007/s11481-023-10073-y ↗
48. 10.1186/s13024-021-00482-z10.1186/s13024-021-00482-z ↗
49. 10.1186/s12916-023-02967-810.1186/s12916-023-02967-8 ↗
50. 10.1016/j.pharmthera.2021.10804910.1016/j.pharmthera.2021.108049 ↗
51. 10.1038/cddis.2013.7810.1038/cddis.2013.78 ↗
52. 10.1097/01.ALC.0000166944.79914.0A10.1097/01.ALC.0000166944.79914.0A ↗
53. 10.1016/j.preteyeres.2008.02.00210.1016/j.preteyeres.2008.02.002 ↗
54. 10.3390/pharmaceutics904004410.3390/pharmaceutics9040044 ↗
55. 10.1016/j.cbi.2018.12.00410.1016/j.cbi.2018.12.004 ↗
56. 10.1016/j.taap.2015.10.00310.1016/j.taap.2015.10.003 ↗
57. 10.1007/s00125-020-05299-x10.1007/s00125-020-05299-x ↗